IMPAACT 2024 :
Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Two to Less Than 13 Years of Age with and without HIV
Research Area
Tuberculosis
Study Status
In Development